Curis stock has recently drawn increased attention following the latest round of analyst updates, with the consensus price target holding steady at $14.00 per share. While forecasts show little ...

The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase 1/2a leukemia study while it gathers ...

The biotech's shares rode the wave of buyout speculation higher last month. Curis' shares were essentially trading sideways during the early part of the month, but they quickly came to life in the ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Curis is back on investors’ radar after analysts reaffirmed a US$14.00 fair value per ...

LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...

CAMBRIDGE, Mass., Feb 12, 2010 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), announced today that its licensee Debiopharm S.A. ("Debiopharm") has received approval from France's regulatory authority ...

Small-cap biotechnology firm Curis surged as much as 448% on Tuesday after the company released encouraging phase I data for its leukemia treatment, CA-4948. The company said it observed a Marrow ...

What a difference a day makes. Following a serious pop for its stock on Wednesday, given very encouraging news about one of its pipeline drugs, Curis (NASDAQ: CRIS) saw its shares dive by almost 20% ...

Cancer drug specialist Curis (NASDAQ: CRIS) had a Friday to forget. The biotech's share price took a nearly 37% hit after the company reported some disquieting news about a leading pipeline drug.

LEXINGTON, Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, ...

The swoon came shortly after some very good news for the company. Curis released its first-quarter figures after market close on that otherwise glorious Wednesday. During the quarter, the company took ...